Gastric cancer, GIST
Conditions
Interventions
None listed
Sponsors
National Cancer Center Hospital East
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Gastric cancer cohort 1.The age at the date of obtaining the consent is 20 years or more. 2.Histopathologically diagnosed as gastric adenocarcinoma. 3.A diagnosis of any of a. to d. on upper gastrointestinal endoscopy and thoracoabdominal/pelvic CT scan within 60 days before enrollment a. Clinical stage I gastric cancer (T1-2N0M0) b. Clinical stage IIA gastric cancer (T1-2N1-3M0) c. Clinical stage IIB gastric cancer (T3-4aN0M0) d. Clinical stage III gastric cancer (T3-4aN1-3M0) 4.No prior treatment for gastric cancer with eligibility criteria 2-3. and resection is contemplated post-registration. 5.Willing to submit blood and tissue specimens in accordance with the research protocol. 6.Consent has been obtained in writing. Gastric GIST cohort A 1.The age at the date of obtaining the consent is 20 years or more. 2.Gastric GIST is suspected or histopathologically diagnosed as gastric GIST on upper gastrointestinal endoscopy within 60 days prior to enrollment. 3.No obvious distant metastasis or peritoneal dissemination on CT examination of the thorax and pelvis 4.No prior pre-registration treatment for gastric GIST with eligibility criterion 2 and curative resection is contemplated post-registration. 5.Willing to submit blood and tissue specimens in accordance with the research protocol. 6.Consent has been obtained in writing. Gastric GIST cohort B 1.The age at the date of obtaining the consent is 20 years or more. 2.Histopathologically diagnosed as gastric GIST. 3.No obvious distant metastasis or peritoneal dissemination on CT examination of the thorax and pelvis 4.Curative resection for gastric GIST with eligibility criteria 2 and continued use of imatinib for at least 2 years as perioperative therapy or within 6 months of completion of at least 3 years of imatinib as perioperative therapy. 5.Willing to submit blood and tissue specimens in accordance with the research protocol. 6.Consent has been obtained in writing.
Exclusion criteria
Exclusion criteria: Gastric cancer cohort 1. a history of malignancy (including gastric cancer) with a disease-free period of up to 10 years. 2.Duplicate cancers are suspected on chest and pelvic CT scan within 60 days before enrollment. 3. Are pregnant. 4. the attending physician determines that you are unsuitable for enrollment in the study. Gastric GIST cohort A 1.History of malignancy (including gastric GIST) with a disease-free period of up to 10 years. 2.Duplicate cancers are suspected by chest and pelvic CT scan within 60 days before enrollment. 3.Are pregnant. 4.Your physician determines that you are unsuitable for enrollment in the study. Gastric GIST cohort B 1.A history of malignancy (including gastric GIST) with a disease-free period of up to 10 years prior to resection of gastric GIST with eligibility criterion 2. 2.Duplicate cancers are suspected by chest and pelvic CT scan within 60 days before enrollment. 3.Are pregnant. 4.Your physician determines that you are unsuitable for enrollment in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Positive rate of LUNAR assay in Stage-I-III gastric cancer and gastric GIST | — |
Countries
Japan
Contacts
Public ContactYoshiaki Nakamura
National Cancer Center Hospital East Division for the Promotion of Drug and Diagnostic Development
Outcome results
None listed